Impact ledger

Arrowhead Pharmaceuticals, Inc. (ARWR): the developments shaping its investment case

Follow the evidence affecting Arrowhead Pharmaceuticals, Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

Research Arrowhead Pharmaceuticals, Inc. · $399/mo

Test assumptions, examine opportunities, and save your research.

Material developments

2026-09-06 · 2 reports

Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGR

Channel: Potential future revenue streams if their investigational RNAi therapeutic for atopic dermatitis (ARO-AD1) progresses through clinical trials and gains market approval, benefiting from the expanding market.

watch· 1-5y

2026-09-25 · 4 reports

ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share

Channel: Increased competition in the siRNA therapeutic space, potential for new comparative data.

mixed· 3-12m

2026-09-24

Kyverna Therapeutics, Inc. to Complete Rolling BLA Submission for Miv-cel in Q4 2026

Channel: Second-order effect: Kyverna's miv-cel uses an autologous CAR T-cell therapy approach. While not directly competitive, success in CAR T for autoimmune diseases could validate the broader platform and attract investor interest in similar advanced therapy platforms, including RNAi therapies for rare d

watch· 3-12m

Event impact log

10 events mapped to ARWR since 2026-08-19. Evidence through 2026-09-25.

Date	Event	Channel	Direction	Horizon	Impact
2026-09-25	ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share	Increased competition in the siRNA therapeutic space, potential for new comparative data.	mixed	3-12m	0.30
2026-09-25	ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq	Increased investor confidence in RNA-based therapeutics and the broader biotech funding environment. ADARx's focus on RNA-targeting therapies could draw attention to similar companies.	Bullish	1-3m	0.30
2026-09-25	ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share	Increased competition or validation of the siRNA therapeutic platform.	watch	1-3m	0.20
2026-09-25	ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share	Increased investor attention and potential competitive landscape shifts within the siRNA therapeutic space.	watch	1-3m	0.30
2026-09-24	Kyverna Therapeutics, Inc. to Complete Rolling BLA Submission for Miv-cel in Q4 2026	Second-order effect: Kyverna's miv-cel uses an autologous CAR T-cell therapy approach. While not directly competitive, success in CAR T for autoimmune diseases could validate the broader platform and attract investor interest in similar advanced therapy platforms, including RNAi therapies for rare d	watch	3-12m	0.30
2026-09-16	Acumen Pharmaceuticals Projects Cash Runway into Early 2027	Broader investor sentiment towards clinical-stage biotechnology companies, particularly those with significant R&D burn and reliance on future capital raises. Acumen's cash runway news could be a micro-example of a common biotech challenge.	watch	3-12m	0.10
2026-09-06	Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGR	Potential future revenue streams if their investigational RNAi therapeutic for atopic dermatitis (ARO-AD1) progresses through clinical trials and gains market approval, benefiting from the expanding market.	watch	1-5y	0.40
2026-09-06	Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics	Second-order effect: Increased investor interest in companies with pipeline assets targeting atopic dermatitis, even if early-stage. Arrowhead has an RNAi therapeutic (ARO-AD1) in preclinical development for atopic dermatitis.	watch	1-5y	0.40
2026-09-01	Valion Bio, Inc. Follow-On — $7.7M	Arrowhead Pharmaceuticals is another biotech company, though its focus is on RNA interference. The general sentiment around biotech funding, particularly for innovative platforms, could be marginally influenced by such events. This is a very indirect and weak link.	watch	3-12m	0.10
2026-08-19	Vogenx, Inc. IPO — $12M	Potential new competitor in RNAi or related genetic medicine space. While not directly mRNA, the broader genetic medicine field is interconnected. A new, well-funded player could influence R&D trends or partnership opportunities.	watch	3-12m	0.20

Continue this research

Build your Arrowhead Pharmaceuticals, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.